Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.

Inclusion Criteria: * Signed informed consent, * Post-menopausal women ≤75 years, * histologically confirmed invasive breast carcinoma (no distant metastases), * positive hormone receptor status, * continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery Exclusion Criteria: * menopause status maintained by medication, * pre-operative chemotherapy or hormone therapy or radiation therapy, * relapse or second carcinoma or previous cancerous disease, * breast carcinoma in situ, * simultaneous carcinoma of the opposite side or secondary breast, * 10 or more tumour-infiltrated lymph nodes. * serious accompanying diseases